News
5 Things You'll Want to Watch With AbbVie's Q3 Results
If 2017 ended right now, it would go down as AbbVie's (NYSE: ABBV) best ever. The biotech stock's price has risen a little more than the 50% gains AbbVie made during its first year as a....
What's Behind Amgen's Q3 Revenue Decline
When Amgen (NASDAQ: AMGN) announced its second-quarter results in July, the anemic revenue growth was overshadowed by the company's solid earnings increase and its improved full-year guidance. CEO....
Why MacroGenics, Inc. Stock Soared Today
Shares of the clinical-stage oncology and autoimmune disease specialist MacroGenics (NASDAQ: MGNX) ended the day higher by a healthy 17.36% on a whopping 17.5 times the average volume.The....
Biogen Inc Content With "Resilience" of Its Multiple Sclerosis Franchise
Biogen (NASDAQ: BIIB) grew earnings faster than revenue in the third quarter, which is what investors should be looking for from any mature company in their portfolio. Nevertheless, shares went....
Better Buy: Johnson & Johnson vs. Pfizer
They're two of the oldest, largest, and most respected healthcare companies around. But one has made investors much happier than the other in recent years. Johnson & Johnson (NYSE: JNJ) stock....
Is Pfizer Inc. a Buy?
Pfizer Inc. (NYSE: PFE) shares have risen around 12% this year, in step with the iShares US Pharmaceuticals index. With talk of another spinoff and strong sales growth, this big pharma stock looks....
3 Value Stocks for Retirement
Retirement marks the crowning achievement of a lifetime of hard work and frugal saving. However, it does not mark the end of a marathon, as many believe. It merely marks the beginning of what will....
Why Ionis Pharmaceuticals Inc. Slipped This Morning
Shares of Ionis Pharmaceuticals Inc. (NASDAQ: IONS) dipped 13% lower in early morning trading on Tuesday after its most important collaboration partner reported some disturbing third-quarter sales....
In Case You Missed It, Johnson & Johnson Is Undergoing a Major Business Transformation
Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) is what you might call a staple stock. It's a common holding for growth, value, and income investors given that many of the products it....
Better Buy: Gilead Sciences, Inc. vs. Amgen
Amgen (NASDAQ: AMGN) and Gilead Sciences (NASDAQ: GILD) are central figures within the biotech landscape. However, these two titans of the industry are both in the process of refreshing their....
Why Exactech Skyrocketed 31% Today
After agreeing to be taken private by global alternative asset manager TPG Capital, Exactech (NASDAQ: EXAC) jumped 31% today.Exactech makes orthopedic implant devices and related surgical....
A Foolish Take: The Best-Performing S&P 500 Stock This Year
It has been a good year so far for stocks, with the S&P 500 up 15% since the beginning of 2017. But that's just an average of the 500 stocks on the large-cap index; some have done even....
5 Key Drugs Critical to Johnson & Johnson's Future
Johnson & Johnson (NYSE: JNJ) recently shared its third-quarter financial report card with investors, and by all measures, it deserves kudos. However, the stock market rewards investors based....
3 High-Yield Pharmaceutical Stocks
Pharmaceutical stocks are generally an outstanding place to look for sustainable sources of passive income. Even though most companies offer fairly modest yields due to the costly nature of....
Celgene Could Be the Best CAR-T Stock to Buy, Not Gilead Sciences
Gilead Sciences' (NASDAQ: GILD) recently approved Yescarta could be a billion-dollar blockbuster cancer-cell therapy, but the company could face stiff competition from Celgene (NASDAQ:....
Abbott Laboratories Q3 2017 Earnings Conference Call Transcript (ABT)
Abbott Laboratories (NYSE: ABT)Image source: The Motley Fool.Q3 2017 Earnings Conference CallOct. 18, 2017, 9:00 a.m. ET Continue readingSource: Fool.com
3 High-Yield Stocks for Conservative Investors
Conservative equates to cautious. We're talking investing here, of course, and not politics. Conservative investors are by nature cautious. There's nothing wrong with that. After all, Warren....
Here's Why Ignyta Stock Soared as Much as 27.5% Today
Shares of pre-revenue biopharma Ignyta (NASDAQ: RXDX) jumped over 27% Wednesday morning after it announced promising interim results from an ongoing phase 2/3 clinical trial investigating the....
What's Powering Johnson & Johnson's Impressive Quarterly Earnings?
Johnson & Johnson (NYSE: JNJ) surprised investors with better-than-hoped-for top-line and bottom-line performance in the third quarter, and that news sent shares soaring on Tuesday. The....
3 Things You Won't Learn by Focusing on Johnson & Johnson's Headline Figures in Its Q3 Report
Johnson & Johnson (NYSE: JNJ) often kicks things off for the healthcare sector with the release of its quarterly earnings, and once again, the largest healthcare company by market cap....
Better Buy: Ziopharm Oncology, Inc. vs. Celldex Therapeutics
Ziopharm Oncology, Inc. (NASDAQ: ZIOP) and Celldex Therapeutics, Inc. (NASDAQ: CLDX) are both clinical-stage biotechs that could make you rich, but they'll need to carry at least one of their new....
Johnson & Johnson Q3 2017 Earnings Conference Call Transcript (JNJ)
Johnson & Johnson (NYSE: JNJ)Image source: The Motley Fool.Q3 2017 Earnings Conference CallOctober 17, 2017, 8:30 a.m. ETContinue readingSource: Fool.com
Johnson & Johnson Jumps on Pharma Strength
Johnson & Johnson (NYSE: JNJ) has been a behemoth in the U.S. healthcare space for decades. Yet as a mature company, J&J faces the inevitable challenge of finding ways to keep its growth....
Why TransEnterix Stock Is Soaring Today
Shares of the robotic-surgery company TransEnterix (NYSEMKT: TRXC) rose by as much as 69% today in early morning trading. This small-cap healthcare stock has now appreciated by over 200% since the....
3 Drug Stocks Hitting 52-Week Highs: Are They Buys?
October has often been a scary month for stocks. That isn't the case so far this year, though. And it's especially not true for three drug stocks.Biogen (NASDAQ: BIIB), Halozyme Therapeutics....